Belgium, 20 April 2022 – VIB and Flemish Minister of Economy and Innovation Hilde Crevits announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics. Her appointment strengthens VIB’s commitment to focus on the burgeoning fields of data science and personalized health.
Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.
Belgium, 20 April 2022 – VIB and Flemish Minister of Economy and Innovation Hilde Crevits announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics. Her appointment strengthens VIB’s commitment to focus on the burgeoning fields of data science and personalized health.
Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.